Aug 11, 2025 • Benzinga
NEUTRAL
Metagenomi Appoints Laurence Reid, PhD to its Board of Directors - KalVista Pharmaceuticals ( NASDAQ:KALV ) , Metagenomi ( NASDAQ:MGX )
EMERYVILLE, Calif., Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Metagenomi, Inc. MGX ( the "Company" ) , a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced the appointment of Laurence Reid, PhD, to ...
Aug 04, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
CORAL GABLES, Fla., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Catalyst Pharmaceuticals, Inc. ( "Catalyst" or "Company" ) ( Nasdaq: CPRX ) today announced the appointment of Daniel Curran, MD, to its Board of Directors.
Jul 30, 2025 • Benzinga
NEUTRAL
Why Is Takeda Pharma Stock Falling On Wednesday? - Takeda Pharmaceutical Co ( NYSE:TAK )
Q1 profit rose 30% Y/Y to ¥124.2 billion ( $834 million ) ; EPS of $0.52 beat estimates. Vyvanse U.S. sales dropped 47% to ¥57.9 billion; Takhzyro, IG, Adcetris saw gains. Missed the rally? Learn exactly where the next leaders are emerging here.
Jul 24, 2025 • GlobeNewswire
NEUTRAL
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors
PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® ( cabozantinib ) for adult patients with unresectable or metastatic, well differentiated pancreatic ( pNET ) and extra-pancreatic ( epNET ) neuroendocrine tumors who have progressed following ...
Jun 25, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Ocular Therapeutix ( OCUL ) Moves 8.6% Higher: Will This Strength Last?
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Jun 20, 2025 • GlobeNewswire
NEUTRAL
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
PARIS, FRANCE, 20 June 2025 - Ipsen ( Euronext: IPN. ADR: IPSEY ) announced today that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a positive opinion for Cabometyx® ( cabozantinib ) for adult patients with unresectable or ...